Psychopharmacological treatment of schizophrenia: What do we have, and what could we get?

► Antipsychotic drugs (APD) have little effect on negative and cognitive symptoms in schizophrenia. ► There appear to be few major differences between first and second generation APDs. ► Novel APD strategies focus on serotonin, glutamate, acetylcholine and PDE10. ► In addition, novel cognitive enhancer (5-HT6, H3) are being evaluated. ► A major breakthrough in therapy has yet to be identified.